Personalised cancer drug approved in US
Pembrolizumab is indicated for the treatment of adult and paediatric patients with unresectable or metastatic solid tumours that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
May 28, 2017, 18:21 PM IST